中国宫颈癌消除的2100年预测与预算优化策略:一项建模研究
该建模研究预测,在当前策略下,中国宫颈癌年龄标化发病率到2100年将增至2015年的三倍。若自2020年起在当前预算下采取最优策略(12岁女孩疫苗接种覆盖率达95%,45岁女性城市筛查覆盖率90%、农村33%),城市和农村可分别于2072年和2074年消除宫颈癌。预算翻倍或取消限制可进一步提前消除时间。
要点
- 当前策略下中国宫颈癌发病率将持续上升至2100年。
- 当前预算下最优策略可使城市和农村分别于2072年和2074年消除宫颈癌。
- 增加预算至翻倍或无限制可分别提前至2063—2069年或2057—2060年消除。
核心结论
- 中国宫颈癌发病率在当前策略下将持续增加。
- 自2020年起实施预算优化策略可在2070年代初消除宫颈癌。
- 增加预算可提前至2050年代末消除宫颈癌。
研究设计与样本
- 建模研究,采用 adapted and calibrated hybrid model 估计中国城乡宫颈癌发病率至2100年。
- 评估不同预算约束、HPV疫苗接种和筛查方案,采用预算优化过程选择最佳组合。
主要发现
- 当前策略下,到2100年年龄标化发病率预计增至2015年的三倍。
- 当前预算下最优策略(12岁女孩疫苗接种覆盖率95%,45岁女性一生一次筛查城市覆盖率90%、农村33%)使城市2072年(95%CI 2070-74)、农村2074年(95%CI 2072-76)发病率降至每10万女性4例以下。
- 预算翻倍下,城市2063年(95%CI 2059-66)、农村2069年(95%CI 2066-71)消除。
- 无预算限制且最大化12岁女孩疫苗接种和35—64岁女性每5年筛查覆盖率下,城市2057年(95%CI 2053-60)、农村2060年(95%CI 2057-63)消除。
关键数值与推荐
- 消除定义为年龄标化发病率低于每10万女性4例新发病例的第一年。
- 当前预算下最优策略:12岁女孩HPV疫苗接种覆盖率95%;45岁女性一生一次筛查覆盖率城市90%、农村33%。
临床怎么用
- 在当前预算下优先实施12岁女孩高覆盖率HPV疫苗接种和45岁女性一生一次筛查。
- 增加预算可加速宫颈癌消除进程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of cervical cancer in China is increasing rapidly. We aimed to forecast the age-standardised incidence of cervical cancer in China up to 2100, and to determine the optimal strategy to eliminate cervical cancer under different budget scenarios. METHODS: In our modelling study, we developed an adapted and calibrated hybrid model to estimate the incidence of cervical cancer in urban and rural China until 2100. All 1·15 billion Chinese women living or projected to live during 2015-2100, under the projected trends in ageing, urbanisation, and sexual activity were considered. We assessed several scenarios of budget constraints (a current budget [2012-18], twice the current budget, and no budget constraints), implementation of human papillomavirus vaccination (with different target populations and coverage), and cervical cancer screening characteristics (with different target ages, screening intervals, and coverage). We used a budget optimisation process to select the best available combinations of vaccination and screening. The primary outcomes were the annual incidence of cervical cancer in 2015-2100, and the year of elimination (the first year in which the incidence was expected to be lower than four new cases per 100 000 women). FINDINGS: Under the current strategy, by 2100, the age-standardised incidence of cervical cancer is projected to increase to three times the incidence in 2015. However, if China adopts an optimal strategy under the current budget from 2020 onwards (namely, introducing vaccination of 95% coverage for girls aged 12 years, and expanding coverage of once in a lifetime screening for women aged 45 years of 90% in urban areas and 33% in rural areas), the annual age-standardised incidence of cervical cancer is predicted to decrease to fewer than four new cases per 100 000 women (ie, elimination) by 2072 (95% CI 2070-74) in urban China and 2074 (2072-76) in rural China. If the current budget were doubled from 2020 onwards, elimination would be achieved by 2063 (2059-66) in urban China and 2069 (2066-71) in rural China. The earliest possible year of cervical cancer elimination would be 2057 (2053-60) in urban China and 2060 (2057-63) in rural China, if vaccination coverage for girls aged 12 years and coverage of screening at 5-year intervals for women aged 35-64 years was maximised, with no budgetary restrictions. INTERPRETATION: Cervical cancer incidence in China will continue to increase under current cervical cancer prevention strategies. However, under our budget optimisation strategy from 2020 onwards, cervical cancer could be eliminated as a public health problem by the early 2070s. Elimination could be achieved by the late 2050s by increasing the budget towards vaccination against human papillomavirus and cervical cancer screening. FUNDING: National Natural Science Foundation of China and Chinese Academy of Medical Science Initiative for Innovative Medicine.
引用
- Xia C, Hu S, Xu X, et al. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. Lancet Public Health. 2019. PMID: 31493843. doi:10.1016/S2468-2667(19)30162-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。